Memorial Sloan Kettering Cancer Center, 300 East 66th Street, New York, NY, USA.
Memorial Sloan Kettering Cancer Center, 300 East 66th Street, New York, NY, USA; Weill Medical College at Cornell University, New York, NY, USA.
Hematol Oncol Clin North Am. 2024 Jun;38(3):643-657. doi: 10.1016/j.hoc.2024.01.005. Epub 2024 Feb 28.
Biliary tract cancers continue to increase in incidence and have a high mortality rate. Most of the patients present with advanced-stage disease. The discovery of targetable genomic alterations addressing IDH, FGFR, HER2, BRAFV600 E, and others has led to the identification and validation of novel therapies in biliary cancer. Recent advances demonstrating an improved outcome with the addition of immune checkpoint inhibitors to chemotherapy have established a new first-line care standard. In case of contraindications to the use of checkpoint inhibitors and the absence of targetable alterations, chemotherapy remains to be the standard of care.
胆管癌的发病率持续上升，死亡率也很高。大多数患者就诊时已处于晚期。针对 IDH、FGFR、HER2、BRAFV600E 等靶点的可靶向基因组改变的发现，导致了胆管癌新型治疗方法的鉴定和验证。最近的进展表明，在化疗中加入免疫检查点抑制剂可改善预后，从而确立了新的一线治疗标准。如果存在免疫检查点抑制剂使用禁忌或无可靶向的改变，则化疗仍然是标准治疗。
